Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.

These data demonstrate that intratumoral MAVS expression results in local and systemic tumor antigen-specific T cell responses, which could be combined with PD-L1 ICI to permit effective anti-tumor immunotherapy in ICI resistant cancers.